Travere Therapeutics Scores Accelerated FDA Approval For Rare Kidney Disease Treatment
The FDA granted accelerated approval to Travere Therapeutics Inc’s (NASDAQ:TVTX) Filspari (sparsentan) to reduce proteinuria in adults with primary IgAN at risk…
